GHRH analog raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-06-29. Anything still debated is marked as such rather than presented as settled.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Purity is most often assessed by reversed-phase high-performance liquid chromatography, reported as a percentage of total peak area. Identity is confirmed by mass spectrometry, which yields a molecular ion consistent with the expected sequence. Amino acid analysis and peptide mapping provide additional characterization. Reported purity values are method-dependent, so figures from different laboratories are not always directly comparable without details of column, gradient, and detection wavelength.
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
| Property | Value | Notes |
|---|---|---|
| Molecular weight, DAC form | About 3647 Da | Varies with salt form |
| Molecular weight, non-DAC form | About 3358 Da | MOD GRF(1-29) |
| Solubility class | Water soluble | Also dissolves in polar solvents |
| Reported half-life, DAC form | About five to eight days | Values from human studies |
| Common synonyms | CJC-1295; MOD GRF(1-29) | Name depends on variant |
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
=== Post-Han dynasty === In the centuries that followed, several shorter books tried to summarize or systematize the contents of the Yellow Emperor's Inner Canon. The Canon of Problems (probably second century CE) tried to reconcile divergent doctrines from the Inner Canon and developed a complete medical system centered on needling therapy. The AB Canon of Acupuncture and Moxibustion (Zhenjiu jiayi jing 針灸甲乙經, compiled by Huangfu Mi sometime between 256 and 282 CE) assembled a consistent body of doctrines concerning acupuncture; whereas the Canon of the Pulse (Maijing 脈經; c. 280) presented itself as a "comprehensive handbook of diagnostics and therapy." Around 900–1000 AD, Chinese were the first to develop a form of vaccination, known as variolation or inoculation, to prevent smallpox. Chinese physicians had realised that when healthy people were exposed to smallpox scab tissue, they had a smaller chance of being infected by the disease later on. The common methods of inoculation at the time was through crushing smallpox scabs into powder and breathing it through the nose. Prominent medical scholars of the post-Han period included Tao Hongjing (456–536), Sun Simiao of the Sui and Tang dynasties, Zhang Jiegu (c. 1151–1234), and Li Shizhen (1518–1593).
== Methods == One-place studies exploit manuscript ecclesiastical and civil records to explore the microhistory of the villagers and their lives. In Europe, such records usually date back to about 1600 and include:
=== Copper toxicity === The classic copper-catalyzed azide-alkyne cycloaddition has been an extremely fast and effective click reaction for bioconjugation, but it is not suitable for use in live cells due to the toxicity of Cu(I) ions. Toxicity is due to oxidative damage from reactive oxygen species formed by the copper catalysts. Copper complexes have also been found to induce changes in cellular metabolism and are taken up by cells. There has been some development of ligands to prevent biomolecule damage and facilitate removal in in vitro applications. However, it has been found that different ligand environments of complexes can still affect metabolism and uptake, introducing an unwelcome perturbation in cellular function.
In 1998, Firehouse Subs surpassed 10 locations, and later that year opened the first location outside of Florida. In 2000, the founders decided to take a different approach, using consultants to plan franchise growth. They were able to set up financing for potential franchisees. The second wave of franchising began in 2001. In 2011, Firehouse Subs opened its first franchises in the U.S. territory of Puerto Rico, via local franchisee Caribbean Restaurants. By 2012 the company reached 500 locations, ending the year with nearly 600. In July 2016, Firehouse Subs opened its 1,000th location. In 2015, Firehouse Subs opened its first locations in Canada, with its first location opening in Oshawa, Ontario in October with franchisee OnFire Restaurant Group. Currently, the group operates 50 Canadian restaurants, with plans to open a total of 90 in Ontario alone. The chain also launched a loyalty program. In June 2017, Firehouse Subs opened its first airport location at Jacksonville International. In December 2017, the brand's second airport location opened at Orlando International. In April 2018, the chain opened its first on-campus location at Western New England University. In 2020 the chain opened a location at Jacksonville's Baptist Medical Center. On November 15, 2021, Burger King parent Restaurant Brands International announced that it would acquire Firehouse Subs for $1 billion. The acquisition was completed on December 15, 2021. On June 22, 2023, Firehouse Subs opened its first location outside North America in Zurich, Switzerland.
Water Beer is composed mostly of water. Regions have water with different mineral components; as a result, different regions were originally better suited to making certain types of beer, thus giving them a regional character. For example, Dublin has hard water well suited to making stout, such as Guinness; while Pilsen has soft water well suited to making pale lager, such as Pilsner Urquell. The waters of Burton in England contain gypsum, which benefits making pale ale to such a degree that brewers of pale ales will add gypsum to the local water in a process known as Burtonisation.
Sources: en.wikipedia.org
Starbucks did not market Teavana products in its stores, though the acquisition allowed the expansion of Teavana beyond shopping malls. In January 2015, Starbucks began to roll out Teavana teas into Starbucks stores, both in to-go beverage and retail formats. In November 2017, Starbucks sold Tazo to Unilever for $384 million. Starbucks shut down Teavana in early 2018.
Together with his Ph.D. student Hung Tung Tran Prof. Rode developed the practical and flexible visualization software Molvision® capable of interactively analyzing dynamic simulation data. In 2003 Dr. Tran was awarded with a European Innovation Award for the development of this program.
=== 1968–1999 === In 1968, Environmental Sciences Corporation was established in Seattle, Washington, manufacturing equipment related to laboratory animals. In 1972, it acquired and took the name of Hazleton Laboratories, a contract laboratory that conducted toxicology testing. In 1977, Corning Inc. purchased a stake in Hazleton and in 1987, it acquired the remainder of the company for $115 million. By 1982, Hazleton was the largest independent biological testing company and life sciences laboratory in the U.S. and the largest laboratory equipment manufacturer worldwide. The company carried out animal toxicology tests of drugs, cosmetics, pesticides, and industrial chemicals, and bred rhesus monkeys and beagles for its own labs, as well as for chemical and drug companies, hospitals, universities and government agencies. It offered chemical analysis of new compound products for various industries, tested chemicals for gene mutations, and carried out research with monoclonal antibodies. It sold the equipment manufacturing unit in the mid-1980s. In 1989, Corning Glass Works acquired G.H. Besselaar Associates, which conducted clinical trials for drug approvals. In 1990, Hazleton acquired Microtest, a molecular toxicology center in York, England. Corning Glass Works changed its name to Corning, and folded Besselaar and Hazelton into a new subsidiary, Corning Lab Services. In 1991, Corning Lab Services acquired SciCor. In 1992, it acquired Philadelphia Association of Clinical Trials.
The extracted DNA should be stored for as short a time as possible, and the conditions for storage should be chosen to minimize the risk of degradation. In general, the extracted DNA should be stored under the best possible conditions to ensure its stability and integrity for downstream applications.
Sources: en.wikipedia.org
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.
The DAC form carries a maleimide group that binds albumin and extends circulation time. The non-DAC form lacks this group and clears much faster. Both share the same receptor-binding core.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Activation raises cyclic AMP and promotes growth hormone release. Normal feedback pathways remain part of the response.
Cool, dark, and dry conditions are standard, with storage at minus twenty degrees Celsius or below. Desiccant and sealed vials limit moisture uptake. Repeated warming and cooling of the container is generally avoided.